Skip to content

A Double-Blind, Randomized, parallel (adaptive) clinical study to evaluate the efficacy and safety of 3 different types of formulations on bowel function.

A Double-Blind, Randomized, parallel (adaptive) clinical study to evaluate the efficacy and safety of 3 different types of formulations on bowel function. - Bowel Function Study.

Status
Active, not recruiting
Phases
Phase 3
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/02/017407
Enrollment
270
Registered
2019-02-04
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

ITC Life Science and Technology center
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Elderly with digestive complaints (Bowel Function)} - Male or Female Age 55-65 years. (E.g. Documented History of Chronic Constipation, IBS, Diarrhea, Stomach pain etc. (For Group â??A ) 2. Constipated Subjects (complaints of hard and lumpy stools) â?? Male or Non-pregnant Female Age 18- 50 years ( For Group â?? B ) 3. Healthy subjects (as defined by medical history & physical examination)-male or non-pregnant female â?? Age 18- 50 years (For Group C ) 4. Rome-III diagnostic criteria prescribed for IBS. (For Group â?? B) (Annexure I) 5.Recurrent abdominal pain or discomfort at least 3 days per month in the last 3 months associated with changes in frequency of stool. (Group-B) 6.Relief of pain or discomfort with defecation. (Group â?? B) 7. Capability to provide written informed consent (For all Groups)

Exclusion criteria

Exclusion criteria: 1.The subject has a serious, unstable medical condition,such as lung disease,uncontrolled blood pressure,uncontrolled thyroid function,a physical or medical disability or an advanced medical condition. 2.The subject had previous significant gastric or intestinal surgery except appendectomy and gall bladder surgery. 3.IBS sub type other than IBS associated with Constipation. 4.Diarrhea more than 3 bowel movements per day. 5.Antibiotic use within 4 weeks of randomization. 6.Pregnant or lactating women. 7.Subjects on the ongoing therapies with the drugs known to effect gut motility e.g. Laxatives, prokinetics, etc. 8.Subject with eating disorder. 9.History of alcohol, drug, or medication abuse. 10.Participation in another study with any investigational product (IP) within 3 months of randomization. 11.Subject with any condition that might interfere with the conduct of the study as per Investigatorâ??s opinion. 12.Known allergies to any substance in the study product, including lactose intolerance and galactosemia.

Design outcomes

Primary

MeasureTime frame
â?¢Assessment of Bowel function , stool frequency and consistency, PH, fecal questionerTimepoint: Group A Day 1, Day 14, Day 60, Day 75 Group B&C Day 1, Day 14, Day 28, Day 43

Secondary

MeasureTime frame
â?¢ Bowel function-stool frequency and consistency â?¢ Microflora composition (Lactobacilli, Bifidobacteria) â?¢ Fecal calprotectin â?¢ Abdominal symptoms â?¢ The Quality of Life Scale (QOLS) â?¢ POMS Based assessment â?¢ Physiological assessment for health/ clinical markers(BMI, calf circumference and mid arm circumference Timepoint: Group A Day 1, Day 14, Day 60, Day 75 Group B&C Day 1, Day 14, Day 28, Day 43

Countries

India

Contacts

Public ContactDr Ajay Kumar Gupta

Meenakshi Hospital

drajaykumargupta@gmail.com9871134389

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026